|RAS021-C01||Pre-coated with Anti-SARS-CoV-2 Spike RBD Antibody Microplate||1 plate|
|RAS021-C02||SARS-CoV-2 Spike RBD||10 μg|
|RAS021-C03||Biotin-Anti-SARS-CoV-2 Spike RBD Antibody||10 μg|
|RAS021-C05||10 x Washing Buffer||50 mL|
|RAS021-C06||Dilution Buffer||50 mL|
|RAS021-C07||Substrate Solution||12 mL|
|RAS021-C08||Stop Solution||7 mL|
The unopened kit is stable for at least 1 year from the date of manufacture if stored at 2°C to 8°C, and the opened kit is stable for up to 1 month from the date of opening at 2°C to 8°C.
It is recommended not to freeze thaw more than 3 times for powder.
Your experiment will include 6 simple steps:
a)All reagents were returned to room temperature(20℃-25℃) before use.
b) Add your sample to the plate, take the SARS-CoV-2 Spike RBD as Control sample. The samples and Control sample are diluted by Dilution Buffer.
c) Add a diluted Secondary antibody biotin-Anti-SARS-CoV-2 Spike RBD Antibody to the plate. The Secondary antibody is diluted by Dilution Buffer.
d) Add a diluted Streptavidin-HRP to the plate.
e) Wash the plate and add TMB or other colorimetric HRP substrate.
f) Stop the substrate reaction by add diluted acid. Absorbance (OD) is calculated as the absorbance at 450 nm minus the absorbance at 650 nm to remove background prior to statistical analysis. The OD Value reflects the amount of protein bound.
This assay kit employs a standard sandwich-ELISA format providing a rapid detection of SARS-CoV-2 Spike RBD. The kit consists of pre-coated Anti-SARS-CoV-2 Spike RBD Antibody Microplate, SARS-CoV-2 Spike RBD as Control, biotin-Anti-SARS-CoV-2 Spike RBD antibody and HRP-Streptavidin. Detection is performed using HRP-Streptavidin with sensitivity of 12 pg/mL (QC tested).
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.